Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings

Conestoga SMid Cap Composite fell 10.24% net-of-fees in Q1, trailing the Russell 2500 Growth Index by 672 bps as the portfolio lagged broader small/mid growth benchmarks. Performance was supported by aerospace and defense strength, where demand and backlog remain robust, but Repligen underperformed on a more measured outlook and lingering end-market demand concerns. The update is primarily portfolio-commentary rather than a market-moving catalyst.

Analysis

The key takeaway is not simply that defense is working; it is that backlog visibility is now translating into a lower-uncertainty earnings stream, which should support multiple expansion for suppliers with clean execution and recurring service content. The second-order winner is likely the industrial supply chain behind aerospace/defense programs: avionics, specialty materials, testing, and maintenance vendors can benefit as primes de-risk schedules and pull through higher-volume procurement. That said, once backlog becomes the dominant bullish narrative, the trade becomes more vulnerable to any slip in delivery cadence or budget timing than to demand itself.

On the other side, life-science tools names like RGEN are in the classic "good company, harder tape" setup: not a thesis break, but a valuation reset risk as buyers demand evidence that end-market digestion has stabilized. The near-term catalyst path is asymmetric over the next 1-2 quarters, because even modest soft guidance or commentary about ordering patterns can keep multiple compression in place. If end-markets re-accelerate, the upside can be sharp, but the burden of proof sits with management rather than investors.

The contrarian view is that the market may be over-rotating toward defense durability and underpricing how much of the good news is already embedded in suppliers with stretched expectations. For aerospace/defense exposure, the cleaner way to express the theme is via names with operating leverage to backlog conversion rather than the highest-multiple winners; for RGEN, patience may be rewarded if the stock trades below historical growth-quality bands while fundamentals remain intact. In both cases, the next leg will likely be driven by guidance revisions rather than the quarter itself.

Key Decisions for Investors

• Go long aerospace/defense suppliers with backlog conversion leverage for the next 3-6 months; use pullbacks to build, because the market is still underestimating how much visible demand supports FY26 earnings power.
• Fade the highest-multiple defense beneficiaries into strength: trim longs after sharp post-earnings runups, since backlog visibility is already well telegraphed and upside now depends on flawless execution.
• Initiate a tactical short or put spread in RGEN for 1-2 quarters if channel checks remain soft; risk/reward favors downside because guidance sensitivity is still higher than the stock's ability to re-rate on one solid print.
• Pair trade: long defense supply-chain beneficiaries / short select life-science tools names for 2-4 months, targeting multiple divergence if defense backlog confidence persists and end-market demand in tools remains uneven.
• If RGEN falls toward a historical support valuation band while management commentary stabilizes, cover shorts and consider a starter long for a 6-12 month reversion trade.